Volequin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Volequin

Property Description
Active Ingredient Levofloxacin hemihydrate
Form Tablet, oral solution, intravenous injection
Pharmacological Class Fluoroquinolone Antibiotic
Common Use Overcoming bacterial infections
Origin Synthetic (chemically synthesized)

What Type of Medicine is Volequin?

Volequin is a prescription-only antimicrobial preparation whose active ingredient is Levofloxacin. This medication belongs to the potent Fluoroquinolone class of antibiotics, primarily used to combat systemic bacterial infections. Levofloxacin is clinically recognized for its reliable spectrum of activity against both Gram-positive and Gram-negative bacteria.

Levofloxacin is specifically a third-generation fluoroquinolone and is chemically defined as the purified L-isomer of the older drug Ofloxacin. This purification results in a stereochemically stable, single-entity product. Its classification as a chiral fluorinated carboxyquinolone highlights the drug’s modern chemical design, which provides greater cellular penetration compared to older classes. This capability makes it a preferred option for treating serious infections.

Composition, Forms, and General Purpose

The principal component of Volequin is Levofloxacin hemihydrate. It is supplied in multiple versatile dosage forms to accommodate various patient needs and administration methods. These forms include the standard film-coated tablet and an oral solution for taking by mouth, as well as a specialized solution for intravenous infusion for more immediate systemic delivery in acute settings.

The general therapeutic purpose of the medicine is to eradicate bacterial illness through a bactericidal effect, meaning it actively kills the pathogenic microorganisms. It accomplishes this by selectively disrupting essential bacterial enzymes, such as DNA gyrase and DNA topoisomerase IV. This targeted action prevents bacteria from replicating their genetic material, which is the fundamental mechanism used to overcome persistent bacterial infections and provides a pathway toward recovery.

Regulatory References

  1. Levofloxacin - StatPearls (NIH)
  2. Levofloxacin on WHO Essential Medicines List

What side effects are possible with Volequin?

Possible Side Effects and Safety Information

Official regulatory documents classify the potential adverse reactions of Volequin (Levofloxacin) according to the affected organ system and their frequency in clinical use. These classifications establish the documented risk profile of the medicine.


Frequency and System-Organ Classes

The most Common adverse reactions officially listed, which may affect more than 1 in 100 people, typically involve the Gastrointestinal Disorders (e.g., nausea and diarrhoea) and Nervous System Disorders (e.g., headache and insomnia). Reactions classified as Uncommon include vomiting, constipation, tendinitis, and hypoglycemia. Rare events, affecting fewer than 1 in 1,000 people, include serious cardiac effects like QT interval prolongation and Torsade de Pointes.


Serious Adverse Reactions and Safety Constraints

The official label highlights certain rare, serious adverse reactions. These include severe tendon rupture, most frequently involving the Achilles tendon, which can occur during treatment or up to several months after cessation. Other serious, documented risks are potentially permanent peripheral neuropathy, severe hepatotoxicity (liver injury), and the risk of aortic aneurysm or dissection.

Use of Volequin is subject to specific regulatory constraints. It is generally contraindicated in individuals with a history of hypersensitivity to fluoroquinolones or a history of fluoroquinolone-associated tendon disorders. Population-specific safety considerations are also noted, including an increased risk of tendon and cardiac events in older adults and the requirement for dose reduction in patients with renal impairment.

Overdose and Emergency Response

Overdose with Volequin (Levofloxacin) is formally documented in regulatory labeling and requires immediate attention due to the risk of severe systemic effects. The most commonly reported clinical manifestations involve the Central Nervous System (CNS), presenting as convulsive seizures, tremors, hallucinations, confusion, and dizziness. Gastrointestinal signs, such as nausea and mucosal erosions, may also occur. A critical physiological finding is the potential for crystalluria, which necessitates close renal monitoring.

Seek immediate medical attention is the mandated action following any suspected overdose, especially if severe CNS or cardiac symptoms are present.

Severe or life-threatening outcomes include the potential for QT interval prolongation, which necessitates urgent management due to the risk of serious cardiac arrhythmia. Acute Renal Failure is also a documented complication. Patients with pre-existing renal impairment are noted to be at increased risk of severe toxicity.

Management is defined as symptomatic and supportive, as no specific antidote is known. Regulatory documents describe procedural steps such as gastric emptying and the use of activated charcoal to limit absorption. Due to the cardiac risk, continuous ECG monitoring is required for observation.

Therapeutic Uses of Volequin

What Volequin Treats: Main Uses and Benefits

Volequin (Levofloxacin) is a broad-spectrum antibiotic applied in clinical settings that involve acute or unstable symptom patterns caused by bacterial infection. It is used to manage symptoms related to systemic imbalance and localized functional strain. The medication is indicated for a wide range of bacterial conditions where additional symptomatic support is needed.


The medication is considered relevant for specific, serious infections including Community-Acquired Pneumonia (CAP), complicated and acute Urinary Tract Infections (UTIs), acute pyelonephritis, chronic bacterial prostatitis, and severe Skin and Soft Tissue Infections (SSTIs). It is also applied in high-risk scenarios, such as the management of Inhalational Anthrax and Plague. This provides supportive relief when symptoms become temporarily overwhelming, offering assistance in symptom stabilization.

“This medication is applied across domains where additional symptomatic support is needed, helping to address symptom clusters that may become intense or disruptive.”

Volequin contributes to easing the overall symptom load by addressing the infectious process, which helps manage pronounced manifestations like persistent high fever, accompanying malaise, difficulty breathing, and severe localized pain. This supports the patient during difficult episodes and assists with maintaining functional stability in these often challenging conditions.


Quick Fact: Relevant for Managing Symptoms of Systemic and Localized Discomfort


Acute & Severe Systemic Infections

This antibiotic is commonly used across conditions presenting with acute episodes like severe CAP and acute flare-ups of chronic bronchitis. Its application may assist in managing the overall burden of systemic and febrile symptoms, contributing to general well-being during symptomatic phases.

Complicated Deep-Tissue and Urinary Tract Conditions

Volequin is relevant in contexts marked by conditions presenting with systemic or localized discomfort arising from complicated infections of the kidneys or prostate. It helps address symptoms related to inflammatory or irritative states, assisting with maintaining functional stability in these often challenging conditions.

Regulatory References

  1. DailyMed official labeling for Levofloxacin

Eligibility and Restrictions for Use

Volequin (Levofloxacin) is an antibiotic whose use is strictly governed by mandatory population restrictions detailed in official regulatory documents.

Eligibility Scope

Scope Regulatory Statement
Populations for whom use is contraindicated Hypersensitivity to any quinolone, history of tendon disorders from prior fluoroquinolone use, epilepsy, pregnancy, and breastfeeding.
Age-Group Eligibility Adults (typically ge 18 years of age) are the primary eligible population. Routine use is contraindicated in children and growing adolescents. Pediatric use (ge 6 months) is reserved only for specific life-threatening infections, such as Anthrax or Plague.
Conditional Use Required Patients with impaired renal function (Creatinine Clearance <50 mL/min) are eligible but require conditional monitoring. Older adults (typically ge 60 years) and patients taking systemic corticosteroids must use Volequin under special caution due to increased risks. Use is also avoided in patients with a history of Myasthenia Gravis.

Connection to the overall eligibility profile

The regulatory profile defines absolute non-eligibility based on physiological status and pre-existing conditions that pose specific risks associated with the fluoroquinolone class. Use is strictly limited to patient populations where the established benefit outweighs regulatory-defined risks, with mandatory caution for specific comorbidities.

What should I know about interactions with other medicines?

Volequin Interactions with other medicines and products

Official regulatory information describes several clinically significant interactions with Volequin (Levofloxacin) through both pharmacokinetic and pharmacodynamic mechanisms.


Official Interaction Statements

Classification Interacting Substances Official Regulatory Constraint
Absorption Reduction Multivalent cations (Antacids, Iron salts, Zinc salts, Sucralfate, Didanosine with buffers) Must be separated by at least 2 hours (before or after) to prevent significantly reduced systemic exposure.
Clearance Reduction Probenecid, Cimetidine These substances reduce Volequin's renal clearance, officially raising drug levels in the bloodstream.
Pharmacodynamic Risk Warfarin (Vitamin K Antagonists) The anticoagulant effect may be enhanced, requiring close monitoring of coagulation parameters.
Additive Risk Theophylline, certain NSAIDs (e.g., Fenbufen) Documented potential for an additive effect that may lower the cerebral seizure threshold.
Cardiac Risk Other medicinal products that prolong the QT interval (e.g., Class IA and III Antiarrhythmics) Risk of additive QT interval prolongation and associated cardiac events.
Contraindicated Combination Antiperistaltic medicinal products Prohibited when Clostridium difficile-associated disease (CDAD) is suspected or confirmed.

Population-Specific Interaction Notes

Co-administration with corticosteroids is noted to further increase the risk of tendinopathy (e.g., tendon rupture) specifically in elderly patients (generally over 60 years). Caution regarding reduced renal clearance (with Probenecid or Cimetidine) is heightened in patients with pre-existing renal impairment.

Mechanism of Action

Targeting Essential Bacterial Genomic Enzymes

Volequin's mechanism is defined by its ability to precisely inhibit two core bacterial enzymes: DNA Gyrase (bacterial Topoisomerase II) and DNA Topoisomerase IV. These targets are crucial for the physical maintenance and replication of the bacterial chromosome. The interaction is one of enzyme poisoning, where the drug stabilizes the enzyme-DNA complex after the DNA has been cut, preventing repair.

Mechanism of Irreversible Cell Death

The inhibition of the target enzymes initiates a mechanistic cascade. The resulting accumulation of lethal DNA double-strand breaks and the physical blockade of chromosome separation trigger the bacterial cell's death pathway. This bactericidal effect is the central physiological consequence of the mechanism, leading to rapid, concentration-dependent cell death in susceptible microbes.

Limitations and Mechanisms of Resistance

The bactericidal activity of this mechanism is constrained by bacterial counter-strategies, notably chromosomal mutations that alter the structure of the target enzymes and the upregulation of efflux pump systems. These limitations compromise the core bactericidal action by either reducing the drug's binding affinity or actively lowering the necessary intracellular concentration.

Dosage and Administration Information

How Volequin is Used: Official Administration Guidelines

Volequin (Levofloxacin) is used in clinical practice following precise administration and dosage protocols.


Dosing and Administration Route

The medication is used via two primary routes: oral (tablets and solution) and intravenous (IV) infusion. The standard administration frequency for all adult indications is once daily (every 24 hours). Dosing ranges from 250 mg to 750 mg per day, with the dose and total duration (ranging from 3 to 60 days) being predetermined based on the specific condition being managed. Sequential therapy, where a patient switches from the IV route to the oral route, uses the same milligram-for-milligram dose due to the drug's high bioavailability.


Procedural Constraints and Special Instructions

The way Volequin is taken depends on the specific form:

Administration Constraint Official Instruction
Oral Tablet Intake May be taken without regard to food.
Oral Solution Intake Should be taken 1 hour before or 2 hours after eating.
Chelating Agents Oral forms must be taken at least two hours before or two hours after antacids, iron, or zinc supplements.
IV Infusion Rate Must be administered slowly; for example, a 500 mg dose requires an infusion time of at least 60 minutes to prevent administration-related effects.

Population-Specific Dosing Rules

A dose adjustment is necessary for adult patients with renal impairment (Creatinine Clearance le 50 mL/min) to maintain proper drug levels. While age alone does not necessitate a change, the dose is always adjusted if a patient's kidney function is reduced. For certain serious infections like Inhalational Anthrax, specific weight-based dosing applies to pediatric patients six months of age and older.

Recent Clinical Evidence

Volequin (levofloxacin) is an antibiotic belonging to the fluoroquinolone class. Clinical research has primarily focused on its use in treating bacterial infections across several body systems, including the respiratory tract, urinary tract, and skin structure.

Efficacy in Common Indications

Evidence from multiple randomized controlled trials (RCTs) suggests that Volequin demonstrates clinical and microbiological success rates comparable to certain other standard-of-care antibiotics for community-acquired pneumonia (CAP) and complicated urinary tract infections (cUTI). In a meta-analysis of four Phase III clinical trials, levofloxacin was observed to be effective in treating adult CAP caused by certain macrolide-resistant S. pneumoniae isolates.

Regarding dose optimization for CAP, a short-course 5-day regimen of 750 mg once daily was found to be non-inferior in clinical efficacy to a 7–14 day conventional regimen of 500 mg once daily in some mild-to-moderate patient populations. This finding suggests a potential option for reducing total antibiotic exposure while maintaining a similar treatment outcome.

Novel Research in Drug-Resistant Tuberculosis (TB)

Recent international studies, such as the VQUIN trial, have explored the role of Volequin in preventing multidrug-resistant tuberculosis (MDR-TB) in household contacts of infected individuals. The research indicated that a 6-month course of Volequin was associated with a reduced risk of developing MDR-TB compared to placebo in both adults and children, an area where evidence for preventive treatment was previously limited. Another trial investigating high-dose regimens for active MDR-TB observed that while doses greater than 1,000 mg/day resulted in higher drug exposure, they did not lead to a faster time to sputum culture conversion, suggesting a dose of 1,000 mg/day may achieve the target exposure while being generally well tolerated.

Key Studies & References

  1. Levofloxacin in the prevention of multidrug-resistant tuberculosis in household contacts: a randomized, double-blind, placebo-controlled trial (VQUIN)

Frequently Asked Questions (FAQ)

Common questions about Volequin (FAQ)

Q: What happens if a dose of Volequin is missed?

A: If a dose is missed, official patient information describes how to handle it. It generally advises that the missed dose be skipped and the regular schedule followed if the next scheduled dose is approaching. It is noted in the instructions that patients should not take a double dose.

Q: Does Volequin interact with alcohol?

A: Official guidance describes the need to limit or avoid alcohol intake while using Volequin. This is generally recommended because alcohol may increase the risk of certain adverse reactions, such as dizziness or increased liver strain, and may potentially reduce the medicine's effectiveness.

Q: How long does Volequin stay in your system?

A: The elimination half-life of Volequin is typically described in official pharmacokinetic data as being between 6 and 8 hours in adults with normal kidney function. The half-life refers to the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: Are there any foods that should be avoided while taking Volequin?

A: Official instructions indicate that oral forms of Volequin are described as needing to be separated from products containing certain multivalent cations by at least two hours to prevent significantly reduced absorption. This caution includes taking the medicine separately from certain mineral-fortified foods and dairy products.

Q: Does Volequin interact with grapefruit?

A: While not detailed in the main interaction tables, information generally suggests avoiding the consumption of grapefruit juice during treatment. This is based on the potential for grapefruit juice to affect how the body processes Volequin.

Q: Does taking Volequin require regular blood tests?

A: Routine blood testing is not generally required for all patients taking Volequin. However, specific monitoring, which may involve blood tests, may be considered necessary for patients with severe renal impairment or those taking certain interacting medicines, such as warfarin.

Q: What happens if I take Volequin past its expiration date?

A: The expiration date is the last date the manufacturer can assure the full potency and safety of the medicine. The use of expired doses is generally cautioned against, as the medicine may lose its effectiveness and could increase the risk of developing antibiotic resistance.

Q: Are there specific times of day Volequin should be taken?

A: Volequin is prescribed to be taken once daily. To help maintain a consistent and steady level of the medicine in the body, information suggests taking it at the same time each day.

Q: Do the side effects of Volequin go away over time?

A: While many common adverse reactions may be temporary, regulatory safety warnings state that some serious side effects associated with this class of medicine may be long-lasting, disabling, or potentially irreversible. Patients should be aware of this risk profile.

Q: Why do official documents mention special considerations for patients with diabetes taking Volequin?

A: Official warnings describe an association because quinolone antibiotics have been linked to disturbances in blood glucose homeostasis. This can potentially cause both hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar), particularly in patients with pre-existing diabetes.

Q: Does Volequin cause weight gain?

A: Weight gain is not listed as a common, frequent, or serious adverse reaction in the official regulatory documents for Volequin. Adverse reactions are classified based on findings from clinical trials.

Q: Does Volequin affect sleep?

A: Yes, the official documentation lists insomnia (difficulty sleeping) as a common adverse reaction that may occur with the use of Volequin. This is noted under the classification of Nervous System Disorders.

Q: Is Volequin an antibiotic?

A: Yes, Volequin is classified as a fluoroquinolone antibiotic. Its general therapeutic purpose is to kill bacteria, which is achieved through a bactericidal effect on the pathogenic microorganisms.

Q: Can Volequin cause issues with the liver?

A: Official warnings state that Volequin has been associated with severe and sometimes fatal hepatotoxicity (liver injury). Patients experiencing signs of hepatitis are officially advised that the medicine should be discontinued immediately.

Q: What is the risk of stopping Volequin suddenly?

A: While completing the full course is typically a goal for antibiotics, official instructions indicate that the medicine is to be discontinued immediately if a patient experiences certain serious adverse reactions. These reactions include symptoms of tendinopathy, peripheral neuropathy, or severe central nervous system effects.

Q: Is Volequin habit-forming or addictive?

A: Volequin is an antibiotic, and there are no official reports or regulatory classifications that indicate the medicine is habit-forming or has the potential for dependence or abuse.

Q: Do older adults need a different dose of Volequin?

A: Age alone does not mandate a dose change. However, official labeling indicates that dosing requires adjustment if the patient has impaired renal function. Reduced kidney function is a condition which is more common in older adults.

Q: What should be done if an allergic reaction is suspected with Volequin?

A: If a patient suspects they are experiencing an allergic reaction to Volequin, the general guidance provided to patients is to immediately notify their healthcare provider or seek emergency medical care. Hypersensitivity to quinolones is a contraindication for use.

Q: How does Volequin fit into the general treatment plan for the condition it addresses?

A: Due to the risk of serious adverse reactions, regulatory bodies advise that Volequin should be reserved for use in patients who have no alternative treatment options for certain less severe indications, such as uncomplicated urinary tract infection.

Q: Is Volequin affected by changes in body weight?

A: For general adult use, dosing is based on the infection being treated. However, official guidance indicates that in specific populations, such as pediatric patients for certain life-threatening infections, dosing may be calculated based on or guided by the patient's body weight.

Q: Is Volequin safe for people with heart conditions?

A: Official warnings state that Volequin is associated with a risk of QT interval prolongation, which can lead to a serious heart rhythm issue. The use of this medicine is generally restricted or requires caution in patients with a history of known QT prolongation or low potassium levels (hypokalemia).

Q: Can Volequin be used by people who have a history of seizures?

A: The official label notes that Volequin may lower the seizure threshold. Patients with a history of seizures or epilepsy are identified as having an increased risk and require special caution and monitoring during treatment.

Q: What should I tell my dentist before a procedure if I am taking Volequin?

A: Due to the potential for interactions (such as with blood thinners like warfarin) and known risks (like tendon or cardiac effects), it is generally recognized that patients should inform their dentist or surgeon that they are taking Volequin before undergoing any medical procedure.

How should Volequin be stored and disposed of?

How to Store and Dispose of Volequin?

Volequin (levofloxacin) requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The medication must be kept in its tightly closed original container.

Storage Restriction Applies to
Do Not Freeze and Protect from Light Oral Solution and Injection Forms
Stability After Opening (6 months) Oral Solution Only

All Volequin products must be stored out of the reach of children. Unused or expired medication should be disposed of through an authorized drug take-back program. If a program is unavailable, follow the regulatory guidance to mix the drug with an undesirable substance and seal it before placing it in household trash. Do not flush Volequin down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Volequin found in:

A-Z Index: